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ABSTRACT 
 
The reaction of Benzyl o–vanillin 1 and o–phenylene diamine 2 in dichloromethane produced new 
benzimidazole, 3. The complete assignments of 3 were made using 1D and 2D NMR including COSY, HMQC and 
HMBC NMR in CDCl3 and acetone–d6. The coupling constants J are reported in Hertz, and the differences in the 
peak splittings using both solvents are discussed. 
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INTRODUCTION 
 
Hobrecker prepared the first benzimidazole in 
1872, when he reduced 2–nitro–4–methylacetanilide a to 
obtained the tautomers 2, 5 (or 2, 6)–dimethyl 
benzimidazole b (Scheme 1) [1-2]. Since 
benzimidazoles have a similar structure to purines, 
whose derivatives play important roles in biological 
systems, substituted benzimidazoles show interesting 
biological activities. Many benzimidazoles are 
pharmaceutical agents and are used widely in biological 
system applications [3-8]. Recently, some derivatives of 
benzimidazole were reported and used as antiviral [5-6], 
topoisomerase I inhibitors [9-11], antiproliferative [12], 
antiprotozoal activity of Acanthamoeba castellanii [13],   
 
Scheme 1. First benzimidazole b, prepared by 
Hobrecker in 1872 [1]. 
 
Scheme 2. Synthesis of new benzimidazole 3, I) DCM, 
MgSO4, 2hr. 
antibacterial [14-16], anthelmintics activity of Trichinella 
spiralis [17], anti–inflammatory against [18-19], anti–
HIV [20-24] and also as anticancer [3-4, 25-30]. 
Meanwhile, phenolic and anisolic benzimidazole 
derivatives have been synthesized and evaluated for 
vasodilator and antihypertensive activity [30], while 
other alkyloxyaryl benzimidazole derivatives have been 
tested for the spasmolytic activity [31].  
Recently, we synthesized and characterized 2–
(2–(benzyloxy)–3–methoxyphenyl)–1H–benzimidazole 
3 by FTIR, GC–MS, 1H and 13C NMR spectra from the 
reaction of benzyl o–vanillin 1 and o–phenylene 
diamine 2 in dichloromethane (DCM) (Scheme 2).  
We also obtained the crystal of 3, and its structure 
was determined and studied by X–ray crystallography 
[32-34]. In this work, the complete assignments of 3 
were made using 1D and 2D NMR including APT, 
DEPT–135, COSY, HMQC and HMBC NMR in CDCl3 
and acetone–d6. The coupling constants J were 
reported in Hertz and the differences in the peak 
splittings using both solvents were discussed. 
 
EXPERIMENTAL SECTION 
 
All NMR experiments were performed on 
Bruker Avance 400 UltrashieldTM NMR for 1H operating 
at 400.123 MHz, and Avance 300 NMR spectrometers 
for 13C operating at 71.478 MHz in CDCl3 and acetone–
d6 at 298 K using Bruker XWINNMR software equipped 
with a 5 mm BBI inverse gradient probe [35-36]. 
Chemical shifts were reported downfield in parts per 
million (ppm) from a tetramethylsilane (TMS) reference, 
and coupling constants (J) were measured in Hz. The 
concentration of solute molecule was 100 mg in 1.0 mL 
CDCl3 or acetone–d6.  
 
 RESULTS AND DISCUSSION 
 
The new benzimidazole 3 was synthesized from 
the reaction of 1 and 2 in DCM as a solvent (Scheme 
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2). The benzimidazole 3 was obtained as single crystals 
with melting point of 135–136 °C, (Fig 1 and 2) [15–17]. 
1D 1H and 13C NMR along with 2D COSY, HMQC and 
HMBC experiments were performed to assign all proton 
and carbon chemical shifts. The splitting patterns for the 
aromatic protons of 3 were obtained from the spectra 
acquired using 400 MHz 1H NMR. The 1H and 13C NMR 
chemical shift and coupling constants data in CDCl3 and 
acetone–d6 are listed in Table 1, while Table 2 shows 
the HMQC and HMBC signals of 3. Figure 2 shows the 
chemical structure and the NMR numbering scheme of 
the new benzimidazole 3. 
 
1H NMR 
The 1H NMR spectrum of 3 was obtained and 
shown in Figure 3. Proton H6 displayed doublet of a 
doublet at δ = 8.16–8.14, (J = 8.03 and 1.49 Hz) in 
CDCl3 and 8.03–8.01 ppm, (J = 7.03 and 2.50 Hz) in 
acetone–d6 due to its coupling with H5 and N–H.  
 
Fig 1. The crystal structure of benzimidazole 3, showing 
50% probability displacement ellipsoids and the atom–
numbering scheme, the dashed line indicates an 
intramolecular hydrogen bond. 
 
Fig 2. The chemical structure and the NMR numbering 
scheme of the benzimidazole 3. 
Table 1. 1H and 13C NMR chemical shifts and coupling 
constants of 3 in CDCl3 and acetone–d6
1H NMR (ppm) 13C NMR (ppm) 
Atom No. 
CDCl3 J (Hz) acetone–d6 J (Hz) CDCl3
acetone–
d6
CH3 4.01, s – 3.99, s – 56.49 56.85 
CH2 5.18, s – 5.23, s – 76.85 76.57 
N–H 7.25, d 1.06 7.24, s – – – 
1 – – – – 123.37 124.90 
2 – – – – 146.53 147.07 
3 – – – – 153.26 154.46 
4 7.28, s – 7.21, s – 114.44 115.44 
5 7.09–7.07, dd 8.16, 1.43 
7.21–7.19, 
dd 
8.09, 
2.39 125.29 125.74 
6 8.16–8.14, 
dd 8.03, 1.49 
8.03–8.01, 
dd 
7.03, 
2.50 121.98 122.73 
1` – – – – 136.99 138.31 
2` 7.49–7.47 x 7.47–7.45, 
dd 
9.41, 
3.52 129.40 130.22 
3` 7.45–7.43, t 3.25 7.30, d 2.54 129.32 129.57 
4` 7.46 x 7.31, t 0.99 129.35 129.54 
2`` – – – – 149.62 150.25 
4`` 7.44, d 3.09 7.61–7.60, 
dd 
6.02, 
3.19 
5`` & 6`` 7.27–7.26, t 3.01 7.23–7.22, t 3.03 
123.10* 123.58* 
7`` 7.51–7.49, 
dd 
7.14, 3.71 7.61–7.60, 
dd 
6.02, 
3.19 114.44 116.42 
3a`` & 
7a`` – – – – –** 139.72 
x not clearly observed 
* overlap. 
** not observed. 
 
Table 2. 2D 1H–13C HMQC and HMBC correlations for 
3 in acetone–d6: 
HMQC (ppm) HMBC [J(C,H)] (ppm) 
Atom 
1J 2J 3J 4J 
CH3 56.85 – 154.46, C3 115.44, C4
     
CH2 76.57 138.31, C1`
130.22, C2`
147.07, C2
129.57, C3`
     
N–H – 139.72, C7a``
116.42, C7``
124.90, C1
139.72, C3a``
122.73, C6
123.58, 
C4``,C6``
     
H4 115.44 154.46, C3
122.73, C6
147.07, C2
124.90, C1
     
H5 125.74 
115.44, C4
122.73, C6
124.90, C1
154.46, C3
147.07, C2
     
H6 122.73 124.90, C1
147.07, C2
150.25, C2``
154.46, C3
     
H2` 130.22 129.57, C3`
76.57, CH2
129.54, C4`
129.57, C3`
     
H3` 129.57 
130.22, C2`
129.57, C4`
138.31, C1` 130.22, C2`
     
H4` 129.54 129.57, C3` 130.22, C2` 138.31, C1`
     
H4`` 123.58 
123.58, C5``
139.72, C3a``
123.58, C6``
139.72, C7a``
x 
     
H5`` 123.58 123.58, C4``,C6``
116.42, C7``
139.72, C3a``
139.72, C7a``
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H6`` 123.58 
116.42, C7``
123.58, C5``
123.58, C4``
139.72, C7a``
139.72, C3a``
     
H7`` 116.42 
123.58, C6``
139.72, C7a``
123.58, C5`` 
139.72, C3a``
123.58, C4``
x: not observed. 
 
While the doublet of a doublet observed in CDCl3 at δ = 
7.09–7.07 ppm (J = 8.16 and 1.43 Hz) is assigned to H5 
coupling to H4 in the trisubstituted ring. This proton was 
shown doublet of a doublet and shifted a bit downfield in 
acetone–d6. It was also observed that in CDCl3 and 
acetone–d6 H4 appeared as a singlet at δ = 7.28 and 
7.21 ppm, respectively. Additionally, the proton of N–H 
observed as singlet and resonated at δ = 7.24 ppm in 
acetone–d6, and it appeared as doublet in CDCl3 to δ = 
7.25 ppm, (J = 1.06 Hz). In acetone–d6, the coupling 
between N–H and H6 was observed most probably due 
to the interaction of the solvent with the compound. 
We suggested the triplet of signal in acetone–d6 at δ = 
7.23–7.22 ppm, (J = 3.03 Hz) and at δ = 7.27–7.26 ppm, 
(J = 3.01 Hz) in CDCl3 to be assigned to H5`` and H6`` in 
the benzimidazole ring due to coupling with H4`` and H7``. 
The difference in chemical shift of H4`` and H7`` is also 
apparent in both solvents. In CDCl3, H7`` and H4`` signal 
were found to be separated; H7`` appeared as doublet of 
a doublet at δ = 7.51–7.49 ppm, (J = 7.14 and 3.71 Hz), 
while H4`` appeared as doublet at δ = 7.44 ppm, J cannot 
be determined exactly due to peaks overlapping. 
However, in acetone–d6 both protons shown signal as 
doublet of a doublet at δ = 7.61–7.60 ppm (J = 6.02 and 
3.19 Hz).  
 
Fig 3. 1H NMR spectra of 3 in a) CDCl3 and b) in 
acetone–d6. 
From Figure 3, the signal of the benzyl ring 
protons H2` appeared as doublet of a doublet at δ = 
7.47– 7.44 ppm, (J = 9.41 and 3.52 Hz) in acetone–d6 
although the peaks were not clearly shown in CDCl3. 
The H4` splitting patterns in CDCl3 was not clear due to 
that overlapping of the peaks but it appeared as a 
triplet at δ = 7.31 ppm, (J = 0.99 Hz) in acetone–d6. On 
the other hand, the protons of H3` displayed the signal 
as a triplet at δ = 7.45–7.43 ppm, (J = 3.25 Hz) in 
CDCl3, and as doublet at δ = 7.30 ppm, (J = 2.54 Hz) in 
acetone–d6. The methoxy OMe and methylene CH2 
protons were observed in CDCl3 at δ = 4.01 and 5.18 
ppm, and at δ = 3.99 and 5.23 ppm in acetone–d6, 
respectively. Table 1 shows the chemical shift values of 
3 in both solvents. 
We found both spectra of the benzimidazole 3 
were differed in splitting patterns for some of the 
aromatic protons, which may be due to the solubility of 
3 in both solvents, including some effect from that six–
membered illusory ring, which was formed from the 
intramolecular hydrogen bonding between N–H in the 
benzimidazole ring and the oxygen atom in the benzyl 
ring (Figure 1). 1H–1H COSY and HMBC experiments 
were performed to further confirm that assigned peaks. 
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13C NMR 
The 13C NMR spectra of 3 were obtained and 
shown in Figure 4. The quaternary carbons in 3 were 
identified and recognized by APT and or DEPT–135 
NMR experiments in both solvents. The quaternary 
carbon signals for C3, C2``, C2, C1` and C1 in CDCl3 were 
observed at δ = 153.26, 149.62, 146.53, 136.99 and 
123.37 ppm, respectively. In acetone–d6 these values 
were found to be shifted slightly downfield. The signals 
of the quaternary carbons C3a`` and C7a`` were absent in 
CDCl3, but, APT NMR experiment showed the existing of 
this peak at δ = 138.87 ppm in acetone–d6. A NMR solid 
state study by Claramunt et al. showed that these 
signals appeared at δ = 136.9 ppm [37].The CH2 and 
OMe signals in both solvents were found at about δ = 
76.60 and 56.50 ppm, respectively.  
The spectra showed that some of the carbons in 
the benzimidazole ring overlapped with the other 
carbons in trisubstituted ring. For example, in CDCl3 C7`` 
signal overlapped with C4 at δ = 114.44 ppm, while the 
peaks were separated clearly in acetone–d6, (Figure 4). 
Similarly, carbons C4``, C5`` and C6`` appeared at the 
same chemical shift in both solvents. The carbons in 
trisubstituted ring C6 and C5 were resonated in CDCl3 at 
δ = 121.98 and 125.29 ppm, respectively, while the 
benzyl ring carbons were observed at δ = 129.40, 
129.35 and 129.32 ppm for C2`, C4` and C3` in CDCl3, 
respectively. Table 1 summarizes the chemical shift 
values discussed. 
To confirmed of the assignment signals and the 
overlapping between the aromatic carbons, the proton  
 
Fig 4. 13C NMR spectra of 3 in a) CDCl3 and b) in 
acetone–d6. 
 
coupled 13C NMR spectra of the benzimidazole 3 were 
also conducted. Additionally, the HMQC and HMBC 
experiments done, further aid in assigning the peaks. 
 
1H–1H COSY 
The signals of 3 are also assigned with an aid by 
the COSY experiment. Figure 5 shows the 1H–1H 
COSY NMR spectra of 3 in CDCl3 and acetone–d6. The 
signal in both solvents at δ = 4.01-3.99 ppm, was 
assigned to the methoxy protons, OMe and it showed 
correlations with CH2 at δ = 5.18-5.23 ppm. As 
expected, proton H5 was correlated with H4 and H6 in 
CDCl3 at δ = 7.25 and 8.16–8.14 ppm, respectively. 
Besides H5 and H4, proton H6 show correlations clearly 
with H4 and N–H although this correlation is not 
observed in acetone–d6. H5``, H6`` were observed to be 
correlated with both protons H7`` and H4`` at δ = 7.51–
7.49 and 7.43 ppm in CDCl3 and at δ = 7.61–7.60 ppm 
in acetone–d6.  
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Fig 5. 1H–1H connectivities in the COSY a) in CDCl3, b) 
in acetone–d6 and c) the most important correlations 
observed in COSY and NOESY spectrum of 3. 
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Fig 6. 1H–13C connectivities of 3 in acetone–d6 a) in the 
HMQC, b) in the HMBC and c) the most important 
correlations observed. 
 
 
1H–13C HMQC NMR 
 
The 2D HMQC NMR spectrum was conducted to 
determine which hydrogens are connected to which 
carbons. The HMQC NMR spectrum for 3 was shown in 
Figure 6a, and it confirms the attachments between all 
hydrogens and their corresponding carbons. In acetone–
d6, the signals owing to C4, C7``, C6, C5, C4`, C3` and C2` 
atoms are observed at the respective δ = 115.44, 
116.42, 122.73, 125.74 and 129–130 ppm, while the sig-
nals of the one bond 13C–1H connectivities are also well 
observed for OMe and CH2 atoms whereby the cross 
peaks appear at δ = 56.85 and 76.57 ppm, respectively. 
Table 2 shows the summarized value for HMQC of 3.  
 
1H–13C HMBC spectra 
The 2D HMBC NMR spectrum was conducted to 
examine the long–range 1H–13C connectivities. The 
HMBC NMR spectrum for 3 was shown in Figure 6b. 
The aromatic quaternary carbons are established 
through the connectivities between the carbon and its 
neighboring proton by using a long–range correlated 
HMBC experiment. The signal in acetone–d6 of methoxy 
protons showed 3J–correlation with C3 at δ = 154.46 ppm 
and 4J–correlation with C4 at δ = 115.44 ppm. While the 
protons of CH2 were observed 2J–correlation with C1` 
and 3J–correlation with C2` and C2 at δ = 138.31, 130.22 
and 147.07 ppm, respectively.  
Additionally, the long–range HMBC cross peaks of 
the quaternary carbon C3 with H5 appeared at δ = 7.21–
7.19 ppm and was correlated with H6 at δ = 8.03–8.01 
ppm. Proton H6 was demonstrated to correlate with C2`` 
and C2. H4 and H5 were also observed to be correlated 
with C2. The spectrum also shows that C3a`` and C7a`` 
were correlated with N–H, H6`` and H5`` at δ = 7.24–7.22 
ppm and with H7`` and H4`` at δ = 7.61–7.60 ppm. The 
chemical shifts of the HMBC of 3 are summarized in 
Table 2. 
 
CONCLUSION 
 
We have reported the complete assignments of the 
benzimidazole 3 using 1H, 13C, COSY, HMQC and 
HMBC NMR in both CDCl3 and acetone-d6. Although the 
APT and DEPT–135 spectra were not shown, that 
experiments were performed and the results were 
discussed. Combination of the information gathered from 
experiments done in both solvents helps in assigning 
peak splittings of compound 3. The differences in the 
peak splittings can be seen in a few cases. For example, 
in CDCl3, H7`` displayed doublet of a doublet at δ = 7.51-
7.49 ppm and H4`` signal was overlapped at δ = 7.44 
ppm. While in acetone-d6 both protons shown the 
signal as doublet of doublet at δ = 7.61-7.60 ppm. The 
quaternary carbon peaks of C3a`` and C7a`` were absent 
in CDCl3, but they were observed clearly in acetone-d6 
at δ = 139.72 ppm, and confirmed by APT NMR 
experiment. The cause of these differences may be 
due to the solubility of 3 in both solvents, including 
some effect from that six–membered illusory ring, 
which it was formed from the intramolecular hydrogen 
bonding between N-H in the benzimidazole ring and 
the oxygen atom in the benzyl ring. Overall, 
experiments done in acetone-d6 demonstrated clearer 
peak splittings than in CDCl3. Further reactions using 
the compound to synthesis biologically important 
compounds are in progress. 
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